SEC For	rm 4 FORM	4	UNITE	ED ST/	TES	SEC	CURITIE	ES AI	ND	ЕХСНА	NGE (	CON	/MIS	SION					
		ngton, D.C. 20549								OMB APPROVAL									
Sectio obligation	this box if no n 16. Form 4 c tions may cont ction 1(b).		ST/		ed pursu	NT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								ΗP	Estim	OMB Number: 3235-028   Estimated average burden hours per response: 0.			
1. Name and Address of Reporting Person* <u>Davis Andrew S.</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol Silk Road Medical Inc [SILK]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify					
	(Last) (First) (Middle) C/O SILK ROAD MEDICAL, INC. 1213 INNSBRUCK DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 02/01/2021								A below) below) Chief Commercial Officer				
(Street) SUNNYVALE CA 94089					_ 4. If /									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5	State)	(Zip)																
		Tab	ole I - N	on-Deri	vative	Secu	irities Ac	quire	d, Di	sposed o	of, or Be	enefi	cially	Owned					
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day						Execution Date,			ction Instr.		Securities Acquired (A) o posed Of (D) (Instr. 3, 4 a					6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Ownership		
								Code	v	Amount	(A) or (D)	Price	9	Transact (Instr. 3 a	tion(s)		(Instr. 4)		
Common Stock 02/01/2					2021			<b>M</b> <sup>(1)</sup>		7,472	A	\$	1.46	27,	,274	D			
Common Stock 02/01/20								S <sup>(1)</sup>		7,472	D	\$54	.121(2)	19,	,802	D			
		-	Table II							posed of, convertil				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	a A. Deemed Execution Date, if any		4. Transact Code (In 8)	nsaction of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		5 (1	. Price of Perivative Security nstr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio	e Owners 5 Form: Ily Direct (i or Indire 9 (i) (Instr	Beneficial Ownership ect (Instr. 4)		

					(Instr. 3, 4 and 5)							(Instr. 4)		
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option (right to buy)	\$1.46	02/01/2021	M <sup>(1)</sup>			7,472	05/05/2016 <sup>(3)</sup>	06/23/2025	Common Stock	7,472	\$0	30,217	D	

## Explanation of Responses:

1. The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020.

2. This transaction was executed in multiple trades at price ranging from \$53.61 to \$54.87. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Remarks:

## /s/Mhairi Jones, by power of 02/02/2021 <u>attorney</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.